REFLECT: prospective multicenter non-interventional study evaluating the effectiveness and safety of Sandoz rituximab (SDZ-RTX; Rixathon^®) in combination with CHOP for the treatment of patients with previously untreated CD20-positive diffuse large B-cell lymphoma.

"Declarations Ethics approval and consent to participate: This study was conducted in accordance with applicable Good Clinical Practice guidelines and with the ethical principles laid down in the Declaration of Helsinki. All patients provided written informed consent prior to entry into the study. Patients who participated in the extended observation period (24 months) re-consented. Ethics approval for the study was obtained from the following ethics committees: Landesärztekammer Baden-Württemberg Ethik-Kommission, Sächsische Landesärztekammer – Ethik-Kommission, Ärztekammer Hamburg – Ethik-Kommission, Ethik-Kommission der Ärztekammer Nordrhein, Carl von Ossietzky Universität Oldenburg, Medizinische Ethik-Kommission, Ethik-Kommission der Ärztekammer Westfalen-Lippe und der Westfälischen Wilhelms-Universität Münster, Ethik-Kommission bei der Ärztekammer Niedersachsen, Ethik-Kommission des Landes Sachsen-Anhalt, Geschäftsstelle Dessau, Ethik-Kommission der Universität zu Lübeck, and Ethik-Kommission bei der Landesärztekammer Rheinland-Pfalz.Consent for publication: Not applicable.Author contributions:Manfred Welslau: Conceptualization; Formal analysis; Investigation; Methodology; Writing – review & editing.Boris Kubuschok: Conceptualization; Formal analysis; Investigation; Methodology; Writing – review & editing.Julian Topaly: Conceptualization; Formal analysis; Investigation; Methodology; Writing – review & editing.Burkhard Otremba: Conceptualization; Formal analysis; Investigation; Methodology; Writing – review & editing.Thomas Wolff: Conceptualization; Formal analysis; Investigation; Methodology; Writing – review & editing.Galyna Bryn: Conceptualization; Formal analysis; Investigation; Methodology; Project administration; Writing – original draft; Writing – review & editing.Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The REFLECT study is funded by Hexal AG, a Sandoz company.Competing interests: BO has received honoraria from Hexal AG, a Sandoz company, for lectures and advisory boards. BK has received honoraria and travel support from Roche and Novartis. GB is an employee of Hexal AG, a Sandoz company. MW, JT, and TW have nothing to disclose.Availability of data and materials: Not applicable. Competing interests: BO has received honoraria from Hexal AG, a Sandoz company, for lectures and advisory boards. BK has received honoraria and travel support from Roche and Novartis. GB is an employee of Hexal AG, a Sandoz company. MW, JT, and TW have nothing to disclose."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The REFLECT study is funded by Hexal AG, a Sandoz company."